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Recognising the burden of maternal infection worldwide
Maternal mortality is unacceptably high worldwide, 
with an estimated 300 000 women dying in 2017, of 
which around 200 000 deaths were in sub-Saharan 
Africa.1 Maternal infection, leading to sepsis, is a leading 
contributor to these deaths. Yet data for the incidence 
and cause of maternal infection are scarce.2
In The Lancet Global Health, Mercedes Bonet and 
colleagues3 report findings from a study of maternal 
infection in 52 countries. They report the frequency 
of maternal clinical infections in health facilities, and 
relate them to severe outcomes in 2850 pregnant or 
recently pregnant women worldwide.3 They found 
that 70·4 (95% CI 67·7–73·1) hospitalised women per 
1000 livebirths were managed with maternal infection 
and 10·9 (9·8–12·0) women per 1000 livebirths had an 
infection-related severe maternal outcome. The study 
is an important step forward in showing how common 
and how serious maternal infections are.3
The study investigated the difference in frequency 
of suspected or confirmed maternal infection in 
women delivering in health facilities in low-income and 
middle-income countries and high-income countries. 
The highest risk was observed in upper-middle-
income countries (106·4 [95% CI 98·1–114·7] per 
1000 livebirths), and the lowest was observed in high-
income countries (38·6 [34·1–43·1] per 1000 livebirths), 
reflecting the differential burden of infectious diseases 
between these contexts. However, the difference in 
incidence of maternal infection between the least and 
most well-resourced settings is likely to be greater than 
that reported by Bonet and colleagues.3 The least well-
resourced settings almost always have the highest 
burden of infection, but capability is also most limited. 
Infrequent assessment by frontline workers with limited 
or no access to specialist support leads to systematic 
underreporting of the frequency of infections. Data are 
also poor for causes, as there is frequently no access to 
quality microbiological investigation.
This study defined those managed with maternal 
infection as women in whom there was clinical 
suspicion or diagnosis of infection, a request for culture 
of any bodily fluid, or women who were receiving 
antimicrobial treatment. That these criteria were 
used illustrates a fundamental and important issue, 
which is that as yet there are no standardised criteria 
for maternal possible serious bacterial infection or 
maternal sepsis, applicable worldwide.4 Standard 
clinical criteria that are systematically applied are 
important, particularly in low-resource settings, to 
support identification and treatment of infections. 
They are also essential for comparisons between health 
facilities and studies, in terms of overall or specific 
incidence of particular infectious (or non-infectious) 
causes. In infants, simple algorithms for possible serious 
bacterial infection have been used to guide systematic 
assessment and treatment by frontline health-care 
workers. They have also enabled estimates of the 
number of cases needing treatment,5 studies of causes,6 
and facilitated pragmatic approaches to clinical trials.7
Overall, the evidence base for interventions for 
maternal infection is limited in quantity and quality,8 
even when compared with other very underserved 
groups in low-resource settings, such as neonates. As 
well as the need for randomised controlled trials to 
test specific strategies, working across the continuum 
of reproductive health can be used to increase 
opportunities. Maternal vaccines, such as that for group 
B streptococcus, are expected to be trialled primarily 
against fetal and infant outcomes. Trials such as these, 
or subsequent maternal vaccine probe studies, will 
provide an important opportunity to also assess benefit 
to maternal outcomes, which should not be missed.9
Bonet and colleagues make a substantial contribution 
to the field of maternal infection.3 There remains, 
however, much to be done, particularly for the most 
disadvantaged populations. We need systematic 
and standardised approaches, and to maximise 
opportunities for collaboration across research, policy, 
and practice in reproductive health. Through this, we will 
be able to deliver improvements in the least-resourced 
settings for mothers, and the babies with whom they 
are inextricably linked.
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